
The FDA’s new CBER Safety Council separates post-market biologics safety review from approvals, raising oversight for cell and gene therapy developers.
Click the title above to open the Pharmaceutical Technology April 2020 issue in an interactive PDF format.
over 6 years ago
Biosimilars Poised for Gains in US Marketover 6 years ago
Critical Knowledge for Preparing Auditsover 6 years ago
Can Vaccine Development Be Safely Accelerated?over 6 years ago
Supercritical Fluid Chromatography Systemover 6 years ago
Quaternary Diaphragm Pumpover 6 years ago
Custom-Built Heated Storage Vesselover 6 years ago
Well Plates and Cartridges for Liquid Extractionover 6 years ago
Alternative Cleaning Validation Methods for Biologics




